CN1196487C - 单位剂量形式 - Google Patents

单位剂量形式 Download PDF

Info

Publication number
CN1196487C
CN1196487C CNB008097771A CN00809777A CN1196487C CN 1196487 C CN1196487 C CN 1196487C CN B008097771 A CNB008097771 A CN B008097771A CN 00809777 A CN00809777 A CN 00809777A CN 1196487 C CN1196487 C CN 1196487C
Authority
CN
China
Prior art keywords
compound
unit dosage
dosage form
pde5
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008097771A
Other languages
English (en)
Chinese (zh)
Other versions
CN1384746A (zh
Inventor
W·E·普尔曼
J·S·怀塔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Lilly Icos LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1196487(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos LLC filed Critical Lilly Icos LLC
Publication of CN1384746A publication Critical patent/CN1384746A/zh
Application granted granted Critical
Publication of CN1196487C publication Critical patent/CN1196487C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
CNB008097771A 1999-04-30 2000-04-26 单位剂量形式 Expired - Lifetime CN1196487C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30
US60/132036 1999-04-30

Publications (2)

Publication Number Publication Date
CN1384746A CN1384746A (zh) 2002-12-11
CN1196487C true CN1196487C (zh) 2005-04-13

Family

ID=22452153

Family Applications (2)

Application Number Title Priority Date Filing Date
CN00106987XA Pending CN1292264A (zh) 1999-04-30 2000-04-26 磷酸二酯酶抑制剂及其用途
CNB008097771A Expired - Lifetime CN1196487C (zh) 1999-04-30 2000-04-26 单位剂量形式

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN00106987XA Pending CN1292264A (zh) 1999-04-30 2000-04-26 磷酸二酯酶抑制剂及其用途

Country Status (47)

Country Link
EP (2) EP1173181B3 (enExample)
JP (2) JP4975214B2 (enExample)
KR (2) KR20010020779A (enExample)
CN (2) CN1292264A (enExample)
AT (1) ATE251908T1 (enExample)
AU (3) AU769946C (enExample)
BE (1) BE1012957A5 (enExample)
BR (2) BR0010181A (enExample)
CA (2) CA2371684C (enExample)
CH (2) CH1173181H1 (enExample)
CO (1) CO5170493A1 (enExample)
CZ (1) CZ296534B6 (enExample)
DE (3) DE10021266A1 (enExample)
DK (2) DK1173181T6 (enExample)
DZ (1) DZ3171A1 (enExample)
EA (2) EA005416B1 (enExample)
ES (2) ES2187234A1 (enExample)
FI (1) FI20000976A7 (enExample)
FR (1) FR2795646B1 (enExample)
GB (1) GB2351663A (enExample)
GR (1) GR1003575B (enExample)
HK (1) HK1041204B (enExample)
HR (2) HRP20010778B1 (enExample)
HU (2) HUP0001632A3 (enExample)
ID (1) ID25704A (enExample)
IE (1) IE20000315A1 (enExample)
IL (3) IL135817A0 (enExample)
IT (1) ITMI20000922A1 (enExample)
LT (1) LT4758B (enExample)
LU (1) LU90569B1 (enExample)
LV (1) LV12560B (enExample)
MX (2) MXPA00003997A (enExample)
NL (1) NL1015027C2 (enExample)
NO (2) NO20002097L (enExample)
NZ (2) NZ504163A (enExample)
PE (1) PE20010071A1 (enExample)
PL (2) PL339897A1 (enExample)
PT (2) PT102457A (enExample)
SE (1) SE0001518L (enExample)
SG (1) SG98384A1 (enExample)
SI (2) SI1173181T1 (enExample)
SK (1) SK285415B6 (enExample)
SV (1) SV2002000055A (enExample)
TR (1) TR200001132A2 (enExample)
UA (1) UA72248C2 (enExample)
WO (1) WO2000066099A2 (enExample)
ZA (2) ZA200002058B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1200091B1 (en) * 1999-08-03 2008-07-02 Lilly Icos LLC Pharmaceutical composition comprising tadalafil
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
JP2004533402A (ja) * 2000-06-08 2004-11-04 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅｖインヒビターとしての四環系ジケトピペラジン化合物
WO2002010166A1 (en) * 2000-08-02 2002-02-07 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
DE60219788T2 (de) * 2001-06-05 2008-01-17 Lilly Icos Llc, Wilmington Tetrazyklische verbindungen als pde5-inhibitoren
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0709409A2 (pt) * 2006-03-28 2011-07-12 Javelin Pharmaceuticals Inc composição farmacêutica e método para tratar um mamìfero necessitando de analgesia
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR101663238B1 (ko) 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
JP2019065006A (ja) 2017-09-29 2019-04-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
CA3091597A1 (en) * 2018-02-07 2019-08-15 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
IL126951A0 (en) 1996-05-10 1999-09-22 Icos Corp Carboline derivatives
CZ299633B6 (cs) * 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6462047B1 (en) 1998-09-16 2002-10-08 Icos Corporation Carboline derivatives as cGMP phosphodiesterase inhibitors
CA2346350C (en) * 1998-10-05 2008-01-08 Eisai Co., Ltd. Intraoral quickly disintegrating tablets
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
CA2365782A1 (en) * 1999-04-30 2000-11-09 William E. Pullman Treatment of female arousal disorder
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor

Also Published As

Publication number Publication date
ES2208317T7 (es) 2015-09-15
CN1384746A (zh) 2002-12-11
MXPA00003997A (es) 2002-03-08
FR2795646B1 (fr) 2002-08-16
KR100577057B1 (ko) 2006-05-10
BR0003046A (pt) 2002-07-23
LU90569B1 (fr) 2002-02-27
GB2351663A (en) 2001-01-10
LT4758B (lt) 2001-02-26
DK1173181T3 (da) 2004-02-16
SI20361A (sl) 2001-04-30
NL1015027C2 (nl) 2001-02-14
LT2000035A (lt) 2000-11-27
SK285415B6 (sk) 2007-01-04
EP1415652A3 (en) 2004-05-12
IL146098A0 (en) 2002-07-25
ITMI20000922A1 (it) 2001-10-26
SK15632001A3 (sk) 2002-02-05
UA72248C2 (en) 2005-02-15
ID25704A (id) 2000-11-02
AU2004201988A1 (en) 2004-06-10
PT102457A (pt) 2000-11-30
NL1015027A1 (nl) 2000-10-31
PE20010071A1 (es) 2001-03-22
LV12560A (en) 2000-11-20
JP2000336043A (ja) 2000-12-05
CZ296534B6 (cs) 2006-04-12
HRP20010778B1 (en) 2005-04-30
JP4975214B2 (ja) 2012-07-11
HUP0200912A3 (en) 2003-07-28
HU0200912D0 (en) 2002-04-29
HUP0200912A2 (en) 2002-08-28
CN1292264A (zh) 2001-04-25
PT1173181E (pt) 2004-02-27
SE0001518L (sv) 2000-10-31
ITMI20000922A0 (it) 2000-04-26
FI20000976L (fi) 2000-10-30
ES2208317T3 (es) 2004-06-16
HU0001632D0 (en) 2000-06-28
FI20000976A0 (fi) 2000-04-26
NO20002097D0 (no) 2000-04-25
EA005416B1 (ru) 2005-02-24
SI1173181T1 (en) 2004-04-30
EP1173181B3 (en) 2015-03-25
ATE251908T1 (de) 2003-11-15
IL146098A (en) 2007-06-03
GR1003575B (el) 2001-05-14
MXPA01010837A (es) 2002-11-07
WO2000066099A2 (en) 2000-11-09
EA200101008A1 (ru) 2002-04-25
CH692478A5 (de) 2002-07-15
SG98384A1 (en) 2003-09-19
DZ3171A1 (enExample) 2000-11-09
PL339897A1 (en) 2000-11-06
HUP0001632A3 (en) 2001-12-28
SV2002000055A (es) 2002-07-03
ZA200002058B (en) 2000-11-02
CA2307101C (en) 2003-01-28
WO2000066099A3 (en) 2001-01-18
EA200000355A3 (ru) 2001-02-26
DE60005940D1 (de) 2003-11-20
NZ504163A (en) 2001-11-30
JP2002543116A (ja) 2002-12-17
ES2187234A1 (es) 2003-05-16
DE60005940T3 (de) 2015-08-27
AU769946B2 (en) 2004-02-12
NO322013B3 (no) 2017-11-06
CH1173181H1 (enExample) 2019-07-15
PL197813B1 (pl) 2008-04-30
HU230369B1 (hu) 2016-03-29
CA2371684A1 (en) 2000-11-09
EP1173181A2 (en) 2002-01-23
TR200001132A3 (tr) 2001-01-22
NO20002097L (no) 2001-10-26
EA200000355A2 (ru) 2000-10-30
EP1173181B1 (en) 2003-10-15
GR20000100153A (el) 2000-12-29
HRP20000243A2 (en) 2001-12-31
KR20010020779A (ko) 2001-03-15
DK200000677A (da) 2000-10-31
CZ20013879A3 (cs) 2002-04-17
ZA200108900B (en) 2003-03-26
TR200001132A2 (tr) 2001-01-22
IL135817A0 (en) 2001-05-20
AU769946C (en) 2005-01-13
KR20020008396A (ko) 2002-01-30
DE60005940T2 (de) 2004-07-29
DE10021266A1 (de) 2000-11-16
IE20000315A1 (en) 2001-03-07
SE0001518D0 (sv) 2000-04-26
BE1012957A5 (fr) 2001-06-05
NO20015275D0 (no) 2001-10-29
GB0010199D0 (en) 2000-06-14
NO20015275L (no) 2001-12-06
BR0010181A (pt) 2003-02-25
AU3012900A (en) 2000-11-02
HK1041204B (en) 2004-03-05
DK1173181T6 (en) 2015-04-27
CA2307101A1 (en) 2000-10-30
PL352629A1 (en) 2003-08-25
DE20007861U1 (de) 2000-08-24
FR2795646A1 (fr) 2001-01-05
LV12560B (en) 2001-04-20
NZ514882A (en) 2003-08-29
HUP0001632A2 (hu) 2001-05-28
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
EP1415652A2 (en) 2004-05-06
NO322013B1 (no) 2006-08-07
CO5170493A1 (es) 2002-06-27
AU4490800A (en) 2000-11-17
CA2371684C (en) 2007-10-23
FI20000976A7 (fi) 2000-10-30

Similar Documents

Publication Publication Date Title
CN1196487C (zh) 单位剂量形式
US6943166B1 (en) Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6451807B1 (en) Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US20030144296A1 (en) Daily treatment for erectile dysfunction using a PDE5 inhibitor
HK1065485A (en) Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction
CZ20001536A3 (cs) Orální léčivo
HK1059051A (en) Daily treatment for erectile dysfunction using a pde5 inhibitor

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ICOS CORP.

Free format text: FORMER OWNER: LILLYECKES CO., LTD.

Effective date: 20111115

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20111115

Address after: Washington State

Patentee after: Icos Corp.

Address before: The United States Delaware

Patentee before: Lilly Icos LLC

Effective date of registration: 20111115

Address after: Washington State

Patentee after: Icos Corp.

Address before: The United States Delaware

Patentee before: Lilly Icos LLC

CX01 Expiry of patent term

Granted publication date: 20050413

CX01 Expiry of patent term